- agency
- AMED (Japan Agency for Medical Research and Development)
- amount
- Up to JPY 6.7 billion (~US$44.5 million) per pipeline per some sources; up to 10 billion yen per project. Program created with a subsidy of JPY 350 billion.
- country
- Japan
- eligibility
- Unlisted biopharmaceutical startups with drug candidates in clinical development that have received investment from government-certified venture capital firms (as of August 2025, 30 VCs registered with AMED, including 9 foreign VCs). Targets drug-development projects in nonclinical studies, Phase I or II clinical trials, or exploratory clinical studies; grants are designed to match/double VC investment.